vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and BlueLinx Holdings Inc. (BXC). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $748.9M, roughly 1.3× BlueLinx Holdings Inc.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 0.2%, a 7.5% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs 0.2%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $52.7M). Over the past eight quarters, APTARGROUP, INC.'s revenue compounded faster (2.6% CAGR vs 2.5%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
BlueLinx Holdings Inc. is a wholesale distributor of building and industrial products in the United States. Headquartered in Atlanta, Georgia, Shyam Reddy serves as its President and CEO.
ATR vs BXC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $748.9M |
| Net Profit | $74.3M | $1.7M |
| Gross Margin | — | 14.4% |
| Operating Margin | 11.0% | 1.3% |
| Net Margin | 7.7% | 0.2% |
| Revenue YoY | 13.5% | 0.2% |
| Net Profit YoY | -26.4% | -89.7% |
| EPS (diluted) | $1.13 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | — | ||
| Q3 25 | $961.1M | $748.9M | ||
| Q2 25 | $966.0M | $780.1M | ||
| Q1 25 | $887.3M | $709.2M | ||
| Q4 24 | $848.1M | $710.6M | ||
| Q3 24 | $909.3M | $747.3M | ||
| Q2 24 | $910.1M | $768.4M | ||
| Q1 24 | $915.4M | $726.2M |
| Q4 25 | $74.3M | — | ||
| Q3 25 | $127.9M | $1.7M | ||
| Q2 25 | $111.7M | $4.3M | ||
| Q1 25 | $78.8M | $2.8M | ||
| Q4 24 | $100.9M | — | ||
| Q3 24 | $100.0M | $16.0M | ||
| Q2 24 | $90.5M | $14.3M | ||
| Q1 24 | $83.1M | $17.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 14.4% | ||
| Q2 25 | — | 15.3% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | — | 15.9% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 17.6% |
| Q4 25 | 11.0% | — | ||
| Q3 25 | 14.2% | 1.3% | ||
| Q2 25 | 14.9% | 1.9% | ||
| Q1 25 | 12.8% | 1.5% | ||
| Q4 24 | 14.2% | 1.7% | ||
| Q3 24 | 15.2% | 3.2% | ||
| Q2 24 | 13.8% | 3.1% | ||
| Q1 24 | 12.2% | 3.8% |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 13.3% | 0.2% | ||
| Q2 25 | 11.6% | 0.6% | ||
| Q1 25 | 8.9% | 0.4% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 11.0% | 2.1% | ||
| Q2 24 | 9.9% | 1.9% | ||
| Q1 24 | 9.1% | 2.4% |
| Q4 25 | $1.13 | — | ||
| Q3 25 | $1.92 | $0.20 | ||
| Q2 25 | $1.67 | $0.54 | ||
| Q1 25 | $1.17 | $0.33 | ||
| Q4 24 | $1.48 | $0.67 | ||
| Q3 24 | $1.48 | $1.87 | ||
| Q2 24 | $1.34 | $1.65 | ||
| Q1 24 | $1.23 | $2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $429.4M |
| Total DebtLower is stronger | $1.1B | $598.5M |
| Stockholders' EquityBook value | $2.7B | $623.0M |
| Total Assets | $5.3B | $1.6B |
| Debt / EquityLower = less leverage | 0.43× | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | — | ||
| Q3 25 | $264.8M | $429.4M | ||
| Q2 25 | $169.8M | $386.8M | ||
| Q1 25 | $136.8M | $449.0M | ||
| Q4 24 | $226.2M | $505.6M | ||
| Q3 24 | $327.9M | $526.3M | ||
| Q2 24 | $223.9M | $491.4M | ||
| Q1 24 | $201.1M | $481.3M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | $598.5M | ||
| Q2 25 | $535.1M | $596.4M | ||
| Q1 25 | $561.2M | $596.6M | ||
| Q4 24 | $688.1M | $575.1M | ||
| Q3 24 | $822.7M | $576.0M | ||
| Q2 24 | $681.5M | $574.6M | ||
| Q1 24 | $680.4M | $574.0M |
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.8B | $623.0M | ||
| Q2 25 | $2.7B | $621.3M | ||
| Q1 25 | $2.5B | $636.1M | ||
| Q4 24 | $2.5B | $646.4M | ||
| Q3 24 | $2.5B | $655.6M | ||
| Q2 24 | $2.4B | $652.3M | ||
| Q1 24 | $2.3B | $653.2M |
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.1B | $1.6B | ||
| Q2 25 | $4.9B | $1.6B | ||
| Q1 25 | $4.5B | $1.6B | ||
| Q4 24 | $4.4B | $1.6B | ||
| Q3 24 | $4.6B | $1.6B | ||
| Q2 24 | $4.5B | $1.6B | ||
| Q1 24 | $4.4B | $1.6B |
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | 0.96× | ||
| Q2 25 | 0.20× | 0.96× | ||
| Q1 25 | 0.22× | 0.94× | ||
| Q4 24 | 0.28× | 0.89× | ||
| Q3 24 | 0.32× | 0.88× | ||
| Q2 24 | 0.28× | 0.88× | ||
| Q1 24 | 0.29× | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $58.6M |
| Free Cash FlowOCF − Capex | $96.9M | $52.7M |
| FCF MarginFCF / Revenue | 10.1% | 7.0% |
| Capex IntensityCapex / Revenue | 9.0% | 0.8% |
| Cash ConversionOCF / Net Profit | 2.47× | 35.42× |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | $-25.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | — | ||
| Q3 25 | $177.6M | $58.6M | ||
| Q2 25 | $126.0M | $-26.8M | ||
| Q1 25 | $82.7M | $-33.9M | ||
| Q4 24 | $178.2M | $18.7M | ||
| Q3 24 | $229.3M | $61.8M | ||
| Q2 24 | $143.6M | $35.8M | ||
| Q1 24 | $92.3M | $-31.1M |
| Q4 25 | $96.9M | — | ||
| Q3 25 | $114.3M | $52.7M | ||
| Q2 25 | $62.5M | $-36.4M | ||
| Q1 25 | $25.9M | $-39.8M | ||
| Q4 24 | $112.2M | $-1.5M | ||
| Q3 24 | $162.7M | $53.8M | ||
| Q2 24 | $75.4M | $29.3M | ||
| Q1 24 | $16.7M | $-36.6M |
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.9% | 7.0% | ||
| Q2 25 | 6.5% | -4.7% | ||
| Q1 25 | 2.9% | -5.6% | ||
| Q4 24 | 13.2% | -0.2% | ||
| Q3 24 | 17.9% | 7.2% | ||
| Q2 24 | 8.3% | 3.8% | ||
| Q1 24 | 1.8% | -5.0% |
| Q4 25 | 9.0% | — | ||
| Q3 25 | 6.6% | 0.8% | ||
| Q2 25 | 6.6% | 1.2% | ||
| Q1 25 | 6.4% | 0.8% | ||
| Q4 24 | 7.8% | 2.9% | ||
| Q3 24 | 7.3% | 1.1% | ||
| Q2 24 | 7.5% | 0.8% | ||
| Q1 24 | 8.3% | 0.8% |
| Q4 25 | 2.47× | — | ||
| Q3 25 | 1.39× | 35.42× | ||
| Q2 25 | 1.13× | -6.21× | ||
| Q1 25 | 1.05× | -12.09× | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | 3.86× | ||
| Q2 24 | 1.59× | 2.50× | ||
| Q1 24 | 1.11× | -1.78× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
BXC
| Specialty Products | $525.5M | 70% |
| Structural Products | $223.4M | 30% |
